Is AML susceptible to immunotherapy?

The AML Global Portal were delighted to speak to John DiPersio, Washington University Medical School, St. Louis, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked John DiPersio: Is AML susceptible to immunotherapy? He outlined the current challenges of immunotherapeutic approaches in AML, such as lack of selective targets and life-threatening side-effects, and how they can potentially be overcome.

John DiPersio,Washington University Medical School,ESH,European School of Haematology,AML,acute myeloid leukemia,immunotherapy,Estoril,translational,research,conference,AML Global Portal,AGP,